MIA team receives 2022 Wildfire Highly Cited Publication Award
Read more about the Cancer Institute NSW Awards and the highly cited immunotherapy publication.
MIA shares latest research breakthroughs at world’s largest melanoma conference
Tailoring skin checks based on personal risk, the impact of adjuvant and neo-adjuvant therapies, and the latest in personalised immunotherapy for advanced patients are amongst a plethora of research advances.
Australian researchers identify link between diet, gut microbiome and response to treatment
Diets low in fibre and omega-3 fatty acids linked to poorer response to immunotherapy.
MIA researchers share latest melanoma breakthroughs at ESMO
Researchers and clinicians from Melanoma Institute Australia have played a leading role at the recent ESMO Congress in Paris.
MIA’s Prof Georgina Long AO named as world’s top melanoma expert
Prof Long has been named No 1 Melanoma Expert in worldwide rankings just released by expertscape, based on articles published 2012-2022.
MIA launches world-first tool to predict immunotherapy response
New clinical tool developed by Melanoma Institute Australia hailed a breakthrough in personalising treatment for all cancer patients.
MIA researchers showcase new frontier in melanoma treatment at ASCO 2022
An unprecedented number of breakthroughs to be presented by MIA researchers at world's leading clinical oncology conference.
Global breakthrough in stopping melanoma spreading around body
Immunotherapy after surgery proven effective in reducing disease spread in high risk early stage patients.
FDA approves new combination immunotherapy
Australian researchers and patients were critical to trialling this breakthrough new treatment for advanced melanoma patients.
Neoadjuvant therapy, a breakthrough in Stage III melanoma treatment
In what is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy, a new study has revealed that drug treatment before surgery is effective in preventing deadly spread of the disease.